Publication | Closed Access

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

OncologyPhase 2B/3Afatinib Versus PlaceboClinical TrialsLux-lung 1Immune Checkpoint InhibitorPharmacotherapyCancer TreatmentMedicineRadiation OncologyLung CancerHealth Sciences